Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, PA, 15261, USA.
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, University of Pittsburgh, PA, 15261, USA; UPMC Hillman Cancer Institute, University of Pittsburgh, Pittsburgh, PA, 15261, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Mol Cell Endocrinol. 2021 Jun 1;529:111221. doi: 10.1016/j.mce.2021.111221. Epub 2021 Mar 10.
As the most frequent women's cancer, breast cancer causes the second most cancer-related death in women worldwide. Majority of the breast cancers are hormone receptor-positive and commonly treated by hormone therapy. Thus, the expression levels of hormone receptors signaling pathways are pivotal in the development and therapy of breast cancer. The expression of hormone receptors signaling pathways is not only regulated at the transcription level but also at the post-transcription level by both proteins and RNAs. In addition to that, the function of hormone receptors can also be regulated by RNAs. In this review, we summarize the roles of RNAs in hormone receptor-positive breast cancer. We introduce how mRNA stability and protein function of genes in hormone receptors signaling pathways are regulated by RNA-binding proteins, miRNAs, and lncRNAs. We believe these proteins and RNAs can be potential therapeutic targets of breast cancer.
作为最常见的女性癌症，乳腺癌是全球女性癌症相关死亡的第二大原因。大多数乳腺癌是激素受体阳性的，通常采用激素治疗。因此，激素受体信号通路的表达水平对乳腺癌的发生和治疗至关重要。激素受体信号通路的表达不仅受转录水平的调控，还受蛋白质和 RNA 的转录后调控。此外，激素受体的功能也可以受到 RNA 的调控。在这篇综述中，我们总结了 RNA 在激素受体阳性乳腺癌中的作用。我们介绍了 RNA 结合蛋白、miRNA 和 lncRNA 如何调节激素受体信号通路中基因的 mRNA 稳定性和蛋白质功能。我们相信这些蛋白质和 RNA 可以成为乳腺癌潜在的治疗靶点。
